SEC Filing Summary

Matthew Fust, a director at Crinetics Pharmaceuticals, Inc., reported transactions on September 1, 2026, related to the company's acquisition by Vertex Pharmaceuticals Incorporated. In a merger effective on this date, Fust disposed of 22,836 shares of Common Stock at $85.00 per share, with 5,925 shares remaining post-transaction. Additionally, 5,925 shares were disposed of, resulting in zero shares held. Fust also disposed of various stock options, including 2,092 options at a price of $83.09, 17,500 at $64.68, 12,500 at $40.29, 10,350 at $52.67, and 9,730 at $49.13. These options were canceled and converted into cash payments as part of the merger agreement, with the cash received per option being the difference between the $85.00 merger consideration and the stock option's exercise price, where applicable. All vested and unvested stock options and restricted stock units were canceled and converted into the right to receive cash.